Jun 15 2020
Webinar Description:
The rapid development of immuno-oncology (IO) therapies has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer. Among these, checkpoint inhibitors represent a promising therapeutic approach for a wide range of cancers. For instance, PD-1/PD-L1-targeted monoclonal antibodies (mAbs) are now the standard of care for 16 different types of cancer and tissue-agnostic indications. Among them, Pembrolizumab is the most prescribed.
Unfortunately, the response rate for PD-1 monotherapies is insufficient and synergetic strategies are the next logical step to overcome anti PD-1 resistance and address this unmet need. As of end of 2019, up to 2975 combination trials of anti PD1/PD-L1 agents were under way in combination with 295 targets. This trend is led by combinations of chemotherapies with PD-1 and angiogenesis inhibitors with PD-1. This high number of clinical trials highlights a high potential utility from this combination strategy. There is a real need for a suitable and efficient in vivo model able to screen a wide variety of drug combinations before clinical trials – given the high time and cost of each combination.
During the webinar Dr Yan Wang will discuss:
– Benefits of setting up an early in vivo efficacy evaluation to optimize probability of success for synergistic Immuno-oncology drug candidate
– Learn about chicken embryo model
– Understand the interest of xenograft on chicken embryo model
– Chicken embryo in vivo model for early efficacy and toxicity evaluation of Immuno-oncology drug candidates
– Understand pros and cons of chicken embryo model vs mouse model in Immuno-oncology
– Case studies
Learning Objectives:
– Benefits of setting up an early in vivo efficacy evaluation to optimize probability of success for synergistic Immuno-oncology drug candidate
– Chicken embryo in vivo model for early efficacy and toxicity evaluation of Immuno-oncology drug candidates
– Understand pros and cons of chicken embryo model vs mouse model in immuno-oncology
DOWNLOAD OUR WEBINAR:
Mar 7
2023
Available online
An IN-VIVO Therapeutic Antibody Efficacy Evaluation
Since its introduction, xenografts on the chicken embryo’s ChorioAllantoic Membrane (CAM) has proven extremely valuable for in vivo studies of tumor development, angiogenesis and malignant cell dissemination. The CAM’s ability to efficiently grow inoculated xenogenic tumor cells greatly simplify the analysis of human tumor cell metastasis. [...]
Feb 22
2023
Join us at the ACE DRUG DISCOVERY SUMMIT in London, March 2 -3 !
Join us at the ACE DRUG DISCOVERY SUMMIT in London, March 2 -3 ! This event provides a platform for scientists, researchers and decision makers from all over the world to discuss the latest scientific […]
Feb 6
2023
Available online
Poster: PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy In Ovo
Inovotion's IO results: “PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy In Ovo” [...]
